Insider Selling: Mirati Therapeutics, Inc. (MRTX) SVP Sells $338,527.75 in Stock

Mirati Therapeutics, Inc. (NASDAQ:MRTX) SVP Jamie Christensen sold 14,725 shares of the stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $22.99, for a total value of $338,527.75. Following the completion of the sale, the senior vice president now directly owns 6,395 shares in the company, valued at $147,021.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Jamie Christensen also recently made the following trade(s):

  • On Thursday, November 16th, Jamie Christensen sold 10,275 shares of Mirati Therapeutics stock. The stock was sold at an average price of $18.00, for a total value of $184,950.00.
  • On Thursday, November 2nd, Jamie Christensen sold 7,499 shares of Mirati Therapeutics stock. The stock was sold at an average price of $14.00, for a total value of $104,986.00.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) opened at $24.75 on Friday. Mirati Therapeutics, Inc. has a 52 week low of $2.70 and a 52 week high of $25.20.

Mirati Therapeutics (NASDAQ:MRTX) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.16. equities research analysts predict that Mirati Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in MRTX. Broadfin Capital LLC grew its stake in shares of Mirati Therapeutics by 19.1% in the second quarter. Broadfin Capital LLC now owns 2,490,801 shares of the biotechnology company’s stock worth $9,091,000 after purchasing an additional 400,000 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Mirati Therapeutics by 68.7% in the third quarter. Dimensional Fund Advisors LP now owns 336,667 shares of the biotechnology company’s stock worth $3,939,000 after purchasing an additional 137,104 shares in the last quarter. Royce & Associates LP grew its stake in shares of Mirati Therapeutics by 88.7% in the second quarter. Royce & Associates LP now owns 251,100 shares of the biotechnology company’s stock worth $917,000 after purchasing an additional 118,063 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Mirati Therapeutics by 845.4% in the second quarter. Goldman Sachs Group Inc. now owns 98,251 shares of the biotechnology company’s stock worth $359,000 after purchasing an additional 87,858 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Mirati Therapeutics in the third quarter worth $668,000. 64.68% of the stock is owned by institutional investors.

Several brokerages have weighed in on MRTX. HC Wainwright reaffirmed a “buy” rating on shares of Mirati Therapeutics in a research report on Tuesday, November 7th. Oppenheimer set a $18.00 target price on Mirati Therapeutics and gave the stock a “buy” rating in a research report on Monday, January 8th. Cann reaffirmed a “buy” rating and issued a $18.00 target price on shares of Mirati Therapeutics in a research report on Monday, January 8th. SunTrust Banks reaffirmed a “buy” rating and issued a $13.00 target price on shares of Mirati Therapeutics in a research report on Monday, October 2nd. Finally, Citigroup reaffirmed a “buy” rating and issued a $16.00 target price (up from $8.00) on shares of Mirati Therapeutics in a research report on Tuesday, September 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. Mirati Therapeutics has a consensus rating of “Buy” and an average target price of $14.75.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.truebluetribune.com/2018/01/14/insider-selling-mirati-therapeutics-inc-mrtx-svp-sells-338527-75-in-stock.html.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply